LINC 2026
Few days ago the international LINC 2026 congress in Leipzig has ended, and many important news have been released. We would like to highlight those related to our unique DES technologies brought during the conference:
- NiTiDES™ Sirolimus eluting SFA|P1 SX DES: for the 2nd consecutive year, in the Main Arena 1, Dr. Angelo Cioppa (Mercogliano Hospital- Italy) released the clinical data of an independent All-Comers patients study, performed with the only SX DES releasing Sirolimus that is CE approved: NiTiDES™. The 2 years clinical results remain impressively good: “freedom from TLR = 88,3%” and 0% HALO in a very complex cohort of patients! This confirms that the NiTiDES™ innovative technology can enhance clinical outcomes of complex patients with complex SFA lesions.
- Cre8™ BTK BX DES: During the 2nd congress day, again in the Main Arena 1, Dr. Thoai Minh Tran (Friendship Hospital - Hanoi City, Vietnam) has provided an overview of the South-East Asia BTK patients and treatment as of today. The complexity of the lesions and patients arriving to the hospital very late, when the disease is unfortunately very advanced, has allowed him to underline the key role of Cre8™ BTK in his experience (now merged into an independent all-comers registry) demonstrating the efficacy, safety and versatility of it, promoting the need of a clear role shift of BX DES in BTK: from bail out to primary stenting every time it’s clinically indicated.
